Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Nature Medicine 12, 882-884 (1 August 2006) | doi:10.1038/nm0806-882;
Embryogenesis meets tumorigenesis
&
Abstract
Metastatic melanoma remains one of the deadliest diseases, with a 5-year survival rate of less than 20%. The identification of new biological mediators of disease is the most rational approach to developing drugs to shift these dismal odds.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).